Redox equilibria and the modulation of redox signalling play crucial roles in physiological
processes. Overproduction of reactive oxygen species (ROS) disrupts the body's antioxidant …

In the past two decades, we have witnessed the discovery and development of many potent
and efficacious proteolysis-targeting chimera (PROTAC) degraders, with several in phase I/II …

We report the discovery of ARD-2051 as a potent and orally efficacious androgen receptor
(AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM …

Highlights•AR is a clinically fully validated target for treatment of human prostate
cancer.•PROTAC AR degraders overcome common resistance mechanisms developed …

Abstract Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase which effectively
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …

PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has
become the most popular technology for drug development in recent years. Here, we …

Objectives: Alzheimer's disease (AD) is a serious neurodegenerative disease. Although
many therapeutic strategies have been studied, their clinical applications are immature …

Inhibitor targeting immune checkpoint is a promising new anticancer therapy. Blocking the
interaction between PD-1 and PD-L1 can reverse the immunosuppression state and …

Alzheimer's disease (AD) is a high-incidence neurodegenerative disorder, characterized by
cognitive impairment, memory loss, and psychiatric abnormalities. Ganoderma lucidum is a …

Targeted protein degradation (TPD) technology is based on a unique pharmacological
mechanism that has profoundly revolutionized medicinal research by overcoming limitations …